Medicenna to Announce First Quarter Fiscal 2022 Financial Results and Operational Highlights on Friday, August 13, 2021

Rhea-AI Summary

Medicenna Therapeutics Corp. (NASDAQ: MDNA, TSX: MDNA) will host a conference call and live webcast on August 13, 2021, at 8:30 AM ET to discuss its first quarter fiscal 2022 financial results and operational highlights. The company's focus is on immunotherapy, developing innovative IL-2, IL-4, and IL-13 Superkines as well as Empowered Superkines for cancer treatment. Notable assets include MDNA11, a next-generation IL-2 Superkine, and MDNA55, which has completed a Phase 2b trial for recurrent glioblastoma and has received FDA Fast-Track and Orphan Drug designations.

Positive

• MDNA55 completed a Phase 2b trial for recurrent glioblastoma (rGBM).
• MDNA55 received FDA Fast-Track and Orphan Drug status.

Negative

• None.

TORONTO and HOUSTON, Aug. 04, 2021 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. ("Medicenna" or “the Company") (NASDAQ: MDNA TSX: MDNA), a clinical stage immuno-oncology company, today announced that it will host a conference call and live webcast on August 13, 2021 at 8:30 AM ET to report its first quarter fiscal 2022 financial results and operational highlights.

To access the call, please dial (877) 407-9716 from the United States or (201) 493-6779 internationally, followed by the conference ID: 13721841. To access the live webcast, please go to the investors section of Medicenna’s website at https://ir.medicenna.com/news-and-events/events-and-presentations. Following the live webcast, an archived version of the call will be available on Medicenna’s website.

About Medicenna
Medicenna is a clinical stage immunotherapy company focused on the development of novel, highly selective versions of IL-2, IL-4 and IL-13 Superkines and first in class Empowered Superkines for the treatment of a broad range of cancers. Medicenna's long-acting IL-2 Superkine asset, MDNA11, is a next-generation IL-2 with potentially superior CD122 binding without CD25 affinity thereby preferentially stimulating cancer killing effector T cells and NK cells unlike competing IL-2 programs. Medicenna’s early-stage BiSKITs™ program, (Bifunctional SuperKine ImmunoTherapies) is designed to further enhance the ability of Superkines to treat immunologically “cold” tumors. Medicenna's lead IL4 Empowered Superkine, MDNA55, has completed a Phase 2b clinical trial for rGBM, the most common and uniformly fatal form of brain cancer. MDNA55 has been studied in five clinical trials involving 132 subjects, including 112 adults with rGBM. MDNA55 has obtained Fast-Track and Orphan Drug status from the FDA and FDA/EMA, respectively.

FAQ

When will Medicenna report its Q1 fiscal 2022 results?

Medicenna will report its Q1 fiscal 2022 results on August 13, 2021, at 8:30 AM ET.

What is the focus of Medicenna Therapeutics?

Medicenna focuses on developing immunotherapy treatments using IL-2, IL-4, and IL-13 Superkines.

What is MDNA55 and its significance?

MDNA55 is Medicenna's IL4 Empowered Superkine that has completed a Phase 2b clinical trial for rGBM and has received FDA designations.